GL1X · GenesisL1 explorer

Research workbench

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator

Analyse Fragment-based discovery of mexiletine derivatives as orally bioavailable… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2VIP
Type
protein
Length
247 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Urokinase-type plasminogen activator chain B
EC
3.4.21.73
UniProt
P00749
Ligands
L1R, SO4
Pockets
2 · best druggability 0.44

Structure

x-ray diffraction · 1 distinct chain · 11% helix, 39% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AUrokinase-type plasminogen activator chain B (EC 3.4.21.73)protein24711% helix, 39% strandP00749

Ligands and binding sites

  • L1R · 4-(2-aminoethoxy)-3,5-dichloro-N-[3-(1-methylethoxy)phenyl]benzamide · ligand · chains A
  • SO4 · Sulfate ion · ion · chains A
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11800.440.7533ACT, L1R
2530.350.7914empty

Modifications

Observed in the structure: 5 disulfide (disulfide).

Compared structures

  • 2VIP · Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.